D Thorburn — Page 2 | PubMed Health

PubMed1981

Quantitative cell fusion: derivation and application of theoretical models.

Cell fusion experiments were made on ten cell lines representing seven mammalian species, using inactivated Sendai virus. The extent of fusion was determined microscopically and tabulated as frequencies of cell with different numbers of nuclei. Expected distributions were derived theoretically under certain assumptions concerning the fusion process. A random model was assumed according to which the tendency to fuse depends only on the cell size, expressed as the number of nuclei present in the cell. Three distributions were derived, which were referred to as the simple, additive, and multiplicative models. The additive model pertained to fusions made in cell suspensions and the multiplicative one mainly to fusions in fibroblast monolayers.

Cell Fusion↗

PubMed1975

Use of atropine in patients with acute myocardial infarction and sinus bradycardia.

Fifty-six patients with acute myocardial infarction complicated by sinus bradycardia (SB) were treated with intravenous atropine and monitored in a coronary care unit. Atropine decreased or completely abolished premature ventricular contractions (PVCs) and/or bouts of accelerated idioventricular rhythm in 27 of 31 patients (87%) and brought systemic blood pressure up to normal in 15 of 17 patients (88%) with hypotension. In addition, atropine administration was associated with improved atrioventricular conduction in 11 of 13 patients (85%) with acute inferior myocardial infarction associated with 2 degrees or 3 degrees atrioventricular block. Seven patients developed ten significant adverse effects: ventricular tachycardia or fibrillation in three, sustainedsinus tachycardia in three, increased PVCs in three, and toxic psychosis in one. These major adverse effects correlated with either a higher initial dose of atropine (i.e., 1.0 mg aa compared with the usual 0.5 or 0.6 mg) or a total cumulative dose exceeding 2.5 mg over 21/2 hours. Atropine is the drug of choice for management of patients with SB and hypotension and is effective in the treatment of ventricular arrhythmias as well as conduction disturbances in patients with inferior myocardial infarction. Serious adverse effects, however, preclude use of atropine without careful medical supervision.

Acute Disease↗